These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 38683460)
21. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266 [TBL] [Abstract][Full Text] [Related]
22. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. Hovmand OR; Poulsen ED; Arnfred S J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069 [TBL] [Abstract][Full Text] [Related]
27. Psychedelics and music: neuroscience and therapeutic implications. Barrett FS; Preller KH; Kaelen M Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282 [TBL] [Abstract][Full Text] [Related]
28. The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis. Sicignano D; Hernandez AV; Schiff B; Elmahy N; White CM Curr Med Res Opin; 2024 Feb; 40(2):293-302. PubMed ID: 38111216 [TBL] [Abstract][Full Text] [Related]
29. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Kraehenmann R Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125 [TBL] [Abstract][Full Text] [Related]
30. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898 [TBL] [Abstract][Full Text] [Related]
31. Human behavioral pharmacology of psychedelics. Strickland JC; Johnson MW Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564 [TBL] [Abstract][Full Text] [Related]
32. Drug-drug interactions involving classic psychedelics: A systematic review. Halman A; Kong G; Sarris J; Perkins D J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394 [TBL] [Abstract][Full Text] [Related]
34. The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S J Psychoactive Drugs; 2023; 55(1):1-10. PubMed ID: 35000572 [TBL] [Abstract][Full Text] [Related]
35. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Bender D; Hellerstein DJ Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety of psychedelic medicine: current status and future directions. Wsół A Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530 [TBL] [Abstract][Full Text] [Related]
37. The Past and Future of Psychedelic Science: An Introduction to This Issue. Doblin RE; Christiansen M; Jerome L; Burge B J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970 [TBL] [Abstract][Full Text] [Related]
38. Psychedelic medicines for mood disorders: current evidence and clinical considerations. Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694 [TBL] [Abstract][Full Text] [Related]
39. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Leger RF; Unterwald EM J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567 [TBL] [Abstract][Full Text] [Related]